AstraZeneca completes equity investment agreement with Cellectis
Cellectis is also eligible to receive an investigational new drug (IND) option fee and development
Cellectis is also eligible to receive an investigational new drug (IND) option fee and development
Keimed is a leading wholesale pharma distribution with industry leading operating metrics
Cellares will dedicate multiple Cell Shuttle and Cell Q systems with fully automated, high-throughput quality control for Bristol Myers Squibb’s exclusive use
Desidustat, administered orally is a novel, oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in Chronic Kidney Disease (CKD) patients
Biocon will undertake the development, manufacturing and supply of the drug product, and Biomm will be responsible for obtaining regulatory approval and commercialization in the Brazilian market
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva
The exclusive agreement between AAHI and Croda includes a collaborative effort in research and development
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
Vericiguat works on a pathway not currently targeted by existing heart failure treatments
Subscribe To Our Newsletter & Stay Updated